Literature DB >> 465276

Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.

A Bobik, G L Jennings, P I Korner, P Ashley, G Jackman.   

Abstract

1. Plasma concentrations and heart rate and blood pressure effects of 160 mg oxprenolol as standard rapid release (RR) and slow release (SR) tablets were compared in healthy volunteers. Peak plasma concentrations were lower with SR tablets than with RR tablets and the peak was delayed. 2. Absorption of oxprenolol was described adequately by first order kinetics with both preparations. The apparent half-life of absorption was 0.40 h with RR and 2.4 h for the SR formulation. The apparent elimination half-life of oxprenolol was about 2 h. Relative bioavailabilities of the two formulations were similar. 3. The effectiveness of oxprenolol RR and SR were assessed by their effects on heart rate in severe exercise (EHR) and also by their effects on blood pressure at rest and during exercise. 4. Maximum reductions in these variables coincided with peak oxprenolol concentrations. The effects on EHR and blood pressure parameters had a distinct time course but there was no difference between the time course of inhibition of each variable for the two formulations over 24 h.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465276      PMCID: PMC1429662          DOI: 10.1111/j.1365-2125.1979.tb04640.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  Per cent absorbed time plots derived from blood level and/or urinary excretion data.

Authors:  J G WAGNER; E NELSON
Journal:  J Pharm Sci       Date:  1963-06       Impact factor: 3.534

4.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors:  C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

5.  Absorption of alprenolol in man from tablets with different rates of release.

Authors:  R Johansson; C G Regårdh; J Sjögren
Journal:  Acta Pharm Suec       Date:  1971-03

6.  A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.

Authors:  M J West; M J Kendall; M Mitchard; E B Faragher
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

  7 in total
  11 in total

1.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.

Authors:  M J Kerr; D W Harron; C Kinney; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

3.  Influence of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise.

Authors:  G Jennings; A Bobik; P Korner
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 4.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

5.  Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Authors:  K Balnave; J D Neill; C J Russell; D W Harron; W J Leahey; R Wilson; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.

Authors:  M J Bowles; N S Khurmi; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.

Authors:  J C Petrie; T A Jeffers; O J Robb; A K Scott; J Webster
Journal:  Br Med J       Date:  1980-06-28

9.  Concentration-effect relationships for oxprenolol in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

10.  Comparison of two slow-release formulations of metoprolol with conventional metoprolol and atenolol in hypertensive patients.

Authors:  J H Silas; S Freestone; M S Lennard; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.